annual EBITDA:
$7.53B+$1.29B(+20.65%)Summary
- As of today (July 27, 2025), TAK annual EBITDA is $7.53 billion, with the most recent change of +$1.29 billion (+20.65%) on March 1, 2025.
- During the last 3 years, TAK annual EBITDA has fallen by -$1.45 billion (-16.18%).
- TAK annual EBITDA is now -24.49% below its all-time high of $9.97 billion, reached on March 31, 2021.
Performance
TAK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$958.12M-$647.85M(-40.34%)Summary
- As of today (July 27, 2025), TAK quarterly EBITDA is $958.12 million, with the most recent change of -$647.85 million (-40.34%) on March 1, 2025.
- Over the past year, TAK quarterly EBITDA has increased by +$378.04 million (+65.17%).
- TAK quarterly EBITDA is now -76.00% below its all-time high of $3.99 billion, reached on June 30, 2021.
Performance
TAK quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$7.62B+$378.04M(+5.22%)Summary
- As of today (July 27, 2025), TAK TTM EBITDA is $7.62 billion, with the most recent change of +$378.04 million (+5.22%) on March 1, 2025.
- Over the past year, TAK TTM EBITDA has increased by +$388.17 million (+5.37%).
- TAK TTM EBITDA is now -32.76% below its all-time high of $11.33 billion, reached on September 30, 2021.
Performance
TAK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TAK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.6% | +65.2% | +5.4% |
| 3 y3 years | -16.2% | +44.3% | -17.2% |
| 5 y5 years | +21.8% | +93.2% | +2.3% |
TAK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.2% | +20.6% | -66.4% | +65.2% | -15.5% | +8.0% |
| 5 y | 5-year | -24.5% | +21.8% | -76.0% | +65.2% | -32.8% | +8.0% |
| alltime | all time | -24.5% | +454.7% | -76.0% | +146.2% | -32.8% | +1087.5% |
TAK EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | $7.53B(+20.6%) | $958.12M(-40.3%) | $7.62B(+5.2%) |
| Dec 2024 | - | $1.61B(-37.3%) | $7.24B(-11.9%) |
| Sep 2024 | - | $2.56B(+2.7%) | $8.21B(+16.4%) |
| Jun 2024 | - | $2.49B(+329.6%) | $7.05B(-2.4%) |
| Mar 2024 | $6.24B(-27.1%) | $580.08M(-77.5%) | $7.23B(-11.4%) |
| Dec 2023 | - | $2.58B(+84.2%) | $8.16B(-0.0%) |
| Sep 2023 | - | $1.40B(-47.5%) | $8.16B(-7.6%) |
| Jun 2023 | - | $2.67B(+76.6%) | $8.83B(-2.0%) |
| Mar 2023 | $8.56B(-4.6%) | $1.51B(-41.5%) | $9.01B(+10.4%) |
| Dec 2022 | - | $2.58B(+24.6%) | $8.17B(+3.0%) |
| Sep 2022 | - | $2.07B(-27.3%) | $7.93B(-1.6%) |
| Jun 2022 | - | $2.85B(+329.3%) | $8.05B(-12.4%) |
| Mar 2022 | $8.98B(-9.9%) | $663.84M(-71.6%) | $9.19B(-13.9%) |
| Dec 2021 | - | $2.34B(+6.6%) | $10.68B(-5.7%) |
| Sep 2021 | - | $2.20B(-45.0%) | $11.33B(+3.0%) |
| Jun 2021 | - | $3.99B(+85.7%) | $11.00B(+10.3%) |
| Mar 2021 | $9.97B(+61.2%) | $2.15B(-28.1%) | $9.97B(+19.9%) |
| Dec 2020 | - | $2.99B(+60.2%) | $8.31B(+14.1%) |
| Sep 2020 | - | $1.87B(-37.0%) | $7.29B(-2.1%) |
| Jun 2020 | - | $2.96B(+497.1%) | $7.44B(+17.0%) |
| Mar 2020 | $6.18B(+61.8%) | $496.04M(-74.7%) | $6.36B(-0.4%) |
| Dec 2019 | - | $1.96B(-3.0%) | $6.38B(+18.6%) |
| Sep 2019 | - | $2.02B(+7.6%) | $5.38B(+22.5%) |
| Jun 2019 | - | $1.88B(+261.5%) | $4.40B(+13.7%) |
| Mar 2019 | $3.82B(+3.4%) | $519.95M(-45.8%) | $3.87B(+31.5%) |
| Dec 2018 | - | $959.76M(-7.3%) | $2.94B(-0.8%) |
| Sep 2018 | - | $1.04B(-23.3%) | $2.96B(+8.8%) |
| Jun 2018 | - | $1.35B(-432.7%) | $2.72B(-25.6%) |
| Mar 2018 | $3.69B(+24.0%) | -$405.73M(-141.3%) | $3.66B(-5.8%) |
| Dec 2017 | - | $982.45M(+23.5%) | $3.89B(+1.5%) |
| Sep 2017 | - | $795.78M(-65.2%) | $3.83B(+2.0%) |
| Jun 2017 | - | $2.29B(-1376.8%) | $3.75B(+13.5%) |
| Mar 2017 | $2.98B(+2.2%) | -$179.14M(-119.4%) | $3.31B(-9.5%) |
| Dec 2016 | - | $924.59M(+28.6%) | $3.65B(+0.3%) |
| Sep 2016 | - | $718.97M(-61.0%) | $3.64B(-5.9%) |
| Jun 2016 | - | $1.84B(+999.9%) | $3.87B(+34.3%) |
| Mar 2016 | $2.92B | $167.39M(-81.7%) | $2.88B(+349.7%) |
| Dec 2015 | - | $915.45M(-3.5%) | $641.37M(-47.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $948.47M(+11.2%) | $1.21B(-7.8%) |
| Jun 2015 | - | $853.05M(-141.1%) | $1.32B(-17.8%) |
| Mar 2015 | $1.36B(-66.5%) | -$2.08B(-239.5%) | $1.60B(-61.4%) |
| Dec 2014 | - | $1.49B(+41.5%) | $4.15B(+4.3%) |
| Sep 2014 | - | $1.05B(-7.7%) | $3.98B(-3.4%) |
| Jun 2014 | - | $1.14B(+140.7%) | $4.12B(+1.4%) |
| Mar 2014 | $4.05B(-16.5%) | $473.05M(-64.0%) | $4.06B(+18.5%) |
| Dec 2013 | - | $1.32B(+10.5%) | $3.43B(+33.9%) |
| Sep 2013 | - | $1.19B(+9.9%) | $2.56B(+23.4%) |
| Jun 2013 | - | $1.08B(-778.0%) | $2.07B(+6.6%) |
| Mar 2013 | $4.85B(-5.4%) | -$159.71M(-135.7%) | $1.95B(+12.3%) |
| Dec 2012 | - | $447.83M(-36.4%) | $1.73B(-22.5%) |
| Sep 2012 | - | $703.99M(-26.2%) | $2.24B(-17.1%) |
| Jun 2012 | - | $954.50M(-356.2%) | $2.70B(-15.9%) |
| Mar 2012 | $5.13B(-8.0%) | -$372.52M(-139.1%) | $3.21B(-26.8%) |
| Dec 2011 | - | $952.55M(-18.3%) | $4.39B(-13.7%) |
| Sep 2011 | - | $1.17B(-20.4%) | $5.08B(-9.7%) |
| Jun 2011 | - | $1.47B(+82.5%) | $5.63B(+0.9%) |
| Mar 2011 | $5.57B(-2.9%) | $802.86M(-51.3%) | $5.58B(-0.1%) |
| Dec 2010 | - | $1.65B(-3.7%) | $5.59B(+1.1%) |
| Sep 2010 | - | $1.71B(+21.2%) | $5.53B(+2.5%) |
| Jun 2010 | - | $1.41B(+74.3%) | $5.39B(-5.5%) |
| Mar 2010 | $5.73B(+10.0%) | $811.00M(-49.0%) | $5.70B(-4.7%) |
| Dec 2009 | - | $1.59B(+0.7%) | $5.99B(-5.0%) |
| Sep 2009 | - | $1.58B(-8.6%) | $6.30B(+9.7%) |
| Jun 2009 | - | $1.73B(+57.9%) | $5.75B(+43.0%) |
| Mar 2009 | $5.21B(-2.5%) | $1.09B(-42.6%) | $4.02B(+37.4%) |
| Dec 2008 | - | $1.91B(+87.0%) | $2.92B(+187.0%) |
| Sep 2008 | - | $1.02B | $1.02B |
| Mar 2008 | $5.34B(-4.6%) | - | - |
| Mar 2007 | $5.60B(+15.7%) | - | - |
| Mar 2006 | $4.84B(+9.8%) | - | - |
| Mar 2005 | $4.40B(+4.6%) | - | - |
| Mar 2004 | $4.21B(+10.9%) | - | - |
| Mar 2003 | $3.80B(+17.8%) | - | - |
| Mar 2002 | $3.22B(+19.5%) | - | - |
| Mar 2001 | $2.70B(+26.1%) | - | - |
| Mar 2000 | $2.14B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual EBITDA?
- What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
What is Takeda Pharmaceutical Company Limited annual EBITDA?
The current annual EBITDA of TAK is $7.53B
What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual EBITDA is $9.97B
What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
Over the past year, TAK annual EBITDA has changed by +$1.29B (+20.65%)
What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
The current quarterly EBITDA of TAK is $958.12M
What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly EBITDA is $3.99B
What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
Over the past year, TAK quarterly EBITDA has changed by +$378.04M (+65.17%)
What is Takeda Pharmaceutical Company Limited TTM EBITDA?
The current TTM EBITDA of TAK is $7.62B
What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM EBITDA is $11.33B
What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
Over the past year, TAK TTM EBITDA has changed by +$388.17M (+5.37%)